PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
933.35%
G&A change of 933.35% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
933.35%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.03%. Jim Chanos would check for waste.
933.35%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.69%. Jim Chanos would check for waste.
-14.36%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-933.36%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 0.17%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-933.36%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -0.64%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-14.36%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 1.87%. Seth Klarman would investigate advantages.
-1137.19%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 5.95%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1137.19%
Net income decline while Drug Manufacturers - Specialty & Generic median is 4.39%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-1163.64%
EPS decline while Drug Manufacturers - Specialty & Generic median is 7.91%. Seth Klarman would investigate causes.
-1163.64%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 9.31%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.